The Contract Research Organization (CRO) services market is witnessing steady growth as pharmaceutical, biotech, and medical device companies increasingly outsource research and development activities. CROs offer a wide range of services, including clinical trial management, preclinical testing, regulatory support, and data analysis. This outsourcing model helps reduce costs, accelerate drug development timelines, and improve research efficiency. With the rise of complex therapies and global clinical trials, CROs are playing a critical role in advancing healthcare innovations across the globe.
According to Fortune Business Insights, the global Contract Research Organization (CRO) services market was valued at USD 85.54 billion in 2024. The market is projected to grow from USD 92.27 billion in 2025 to USD 175.53 billion by 2032, exhibiting a CAGR of 9.6% during the forecast period. In 2024, North America dominated the CRO services market with a market share of 50.19%.
Ergomed Group significantly strengthened its U.S. footprint by opening a new office in Kendall Square, Cambridge, Massachusetts in February 2024—an important milestone reflecting the appetite for localized trial services.